L3VLUP
ProSign in

NTRA · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NTRALLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NTRA
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterNTRALLY
Q3 202016 holders, $575m33 holders, $14.1bn
Q4 202015 holders, $741m29 holders, $17.3bn
Q1 202117 holders, $911m24 holders, $23.0bn
Q2 202120 holders, $1.4bn24 holders, $27.8bn
Q3 202117 holders, $1.3bn31 holders, $29.9bn
Q4 202114 holders, $1.2bn31 holders, $34.7bn
Q1 202213 holders, $551m24 holders, $35.3bn
Q2 202214 holders, $473m33 holders, $42.7bn
Q3 202210 holders, $365m31 holders, $43.4bn
Q4 202212 holders, $266m31 holders, $46.6bn
Q1 202314 holders, $658m33 holders, $44.3bn
Q2 202310 holders, $474m37 holders, $59.6bn
Q3 202310 holders, $554m44 holders, $67.6bn
Q4 202312 holders, $695m45 holders, $73.6bn
Q1 202418 holders, $2.0bn41 holders, $95.3bn
Q2 202422 holders, $2.5bn43 holders, $110bn
Q3 202425 holders, $3.6bn45 holders, $107bn
Q4 202428 holders, $4.5bn46 holders, $93.9bn
Q1 202521 holders, $4.6bn42 holders, $98.4bn
Q2 202521 holders, $5.4bn43 holders, $93.2bn
Q3 202523 holders, $4.8bn39 holders, $86.7bn
Q4 202526 holders, $8.1bn41 holders, $123bn
Q1 202620 holders, $6.7bn39 holders, $106bn
Q2 202623 holders, $10.0bn44 holders, $132bn
NTRA

Natera Inc

Holders
23
Reported value
$4.8bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NTRA (9)

ARK Investment Management LLC, Coatue Management LLC, Farallon Capital Management LLC, Maverick Capital Ltd, MFS Investment Management, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Rokos Capital Management LLP

Only LLY (25)

Acadian Asset Management LLC, AllianceBernstein LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Squarepoint Ops LLC, Walleye Capital LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →